CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.
13 Noviembre 2019 - 2:23AM
CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused
on rare diseases that transforms real-world clinical and genetic
data into actionable information for patients, physicians and
pharmaceutical companies, announced today a new data access and
collaboration agreement with Pfizer Inc. (NYSE: PFE). The agreement
grants Pfizer access to CENTOGENE’s data repository, which may be
used in the discovery and validation of novel genetic and
biochemical targets for the potential development of new therapies
for rare diseases.
“With what we believe to be the world’s largest data repository
of epidemiologic, phenotypic and clinical data in orphan diseases,
CENTOGENE is fuelling the global knowledge base of rare disease
patient populations,” explains Arndt Rolfs, CEO of CENTOGENE. “The
potential for furthering the understanding of rare disease is
extremely important for patients around the world, and we hope that
today’s collaboration agreement will help lead to better diagnosis
and potential treatments for patients with rare diseases.”
Under the terms of the agreement, CENTOGENE and Pfizer will work
together to mine the data repository and jointly agree to any
collaborative research projects designed to substantiate results of
data mining. CENTOGENE will receive an upfront payment and will be
eligible for additional research payments under any future
collaborative research projects. Individual-level data from the
repository will be managed, protected and shared with Pfizer in
compliance with international data privacy regulations.
CENTOGENE’s rare disease data repository integrates relevant
structured and unstructured patient data, including clinical
information; health records; and genetic, transcriptomic,
proteomic, and metabolomic data. It also includes longitudinal data
such as biomarker or patient recorded outcome, as well as
diagnostic workflow data.
About CENTOGENECentogene is a commercial-stage
company focused on rare diseases that transforms real-world
clinical and genetic data into actionable information for patients,
physicians and pharmaceutical companies. The Company’s goal is to
bring rationality to treatment decisions and to accelerate the
development of new orphan drugs by using our knowledge of the
global rare disease market, including epidemiological and clinical
data and innovative biomarkers. Centogene has developed a global
proprietary rare disease platform based on our real-world data
repository with over 2.0 billion weighted data points from over
450,000 patients representing 115 different countries as of August
31, 2019, or an average of over 500 data points per patient.
The Company’s platform includes epidemiologic, phenotypic and
genetic data that reflects a global population, and also a biobank
of these patients’ blood samples. Centogene believes this
represents the only platform that comprehensively analyzes
multi-level data to improve the understanding of rare hereditary
diseases, which can aid in the identification of patients and
improve our pharmaceutical partners’ ability to bring orphan drugs
to the market. As of August 31, 2019, the Company collaborated with
over 35 pharmaceutical partners for over 30 different rare
diseases.
CENTOGENE Media Contact:
Ross Bethell
Director, Corporate Communications
press@centogene.com
Pfizer (NYSE:PFE)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Pfizer (NYSE:PFE)
Gráfica de Acción Histórica
De May 2023 a May 2024